Thirdly, is the susceptibility of newborn animals to virus oncogenesis a result of their becoming tolerant to the tumour antigen? This is not the case.8
Adult and newborn mice were inoculated with polyoma virus; ten days and six weeks later their lymphoid cells were tested for sensitization to the virus. This was done by transferring some cells to syngeneic thymectomized animals which had been inoculated with polvoma virus. The lymphoid cells from the adults prevented the development of tumours in the recipients. Cells from the newborns prevented this when taken six weeks after the inoculation of virus, but not wben taken ten days after this. Thus in adults cellmediated immunity is rapidly mounted, being fully established by ten days after the administration of virus (probably earlier), whereas in the newborn cell-mediated immunity develops slowly and is therefore unable to check tumour development.
Even when viruses are transmitted from mother to offspring tolerance to tumour-specific antigens does not develop. We were therefore led to re-examine the classical experiments of Billingham and his colleagues910 on the induction of tolerance by inoculating foreign cells into newborns. Lymphocytes from the "tolerant" animals, in which skin grafts from the donor strain could be permanently accepted, had the capacity to react in vitro against target cells from the donor strain, while their sera specifically blocked this reaction." Hence, it seems very difficult to produce tolerance against cellular-including tumour-antigens, and probably many cases of supposed tolerance are due to blocking or enhancing antibodies.
Leukaemogenic Viruses
The second group of naturally occurring oncogenic viruses in mice is the leukaemogenic viruses. Most mouse strains carry leukaemogenic viruses related to Gross virus, which are transmitted vertically from mothers (and sometimes from fathers) to offspring. For many years it was thought that animals were tolerant to such viruses, producing neither antibody nor cell-mediated immunity. If that were the case, immunosuppression would not be expected to affect tumour development. In fact, it does. Thymectomy cannot be used in this situation, because the production of leukaemia by both the Gross and the Moloney virus requires the presence of a thymus. However, Allison and Law7 found that Moloney lymphoma or leukaemia was greatly potentiated by inoculations of antilymphocytic serum. We have found that the latent period for leukaemia induction in AKR mice, which carry the Gross virus, is shortened by the administration of antilymphocytic serum.
Wahren and Metcalfe"2 have found that lymphocytes from AKR mice are cytotoxic to target cells carrying the Gross virus, so that they can no longer be regarded as tolerant. Other evidence that this is so has been presented by Dore et al. 13 In this case nearly all animals left long enough develop leukaemia (after a latent period of about 300 days). Immunity does not prevent leukaemia but delays its onset, which allows the animals to breed before onset of malignancy. Immunosuppression accelerates the malignancy.
Immunological Surveillance
All these results leave little doubt that the immunological surveillance mechanism operates very efficiently against virusinduced tumours in animals, either preventing or delaying the onset of malignancy. All the tumours so far found in mice receiving long-term immunosuppression have been leukaemias, lymphomas, or mammary tumours, or polyomainduced tumours of the salivary glands or osteosarcomas. In all these cases there is reason to believe that a virus may be concerned in the aetiology. Though the surveillance mechanism may also operate against tumours not induced by viruses, there is no direct evidence that this is the case.
Nevertheless, 'it would be premature to conclude that the tumours occurring in human patients treated with immunosuppressants are virus-induced, though the parallel between animals is striking enough to demand further analysis.
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British Medical J3ournal, 1970, 4, 420-422 The mechanism by which cancer develops remains one of the great mysteries of modern medicine. The concept that it results from a breakdown in "immunological surveillance," which permits the proliferation of an abnormal clone of cells with a selective advantage over other cells, has been widely welcomed as a stimulus to thought and experiment. Keast' has recently summarized the evidence for this hypothesis under four heads. Firstly, cancer in man occurs characteristically at the extremes of life when the immune system is either maturing or is weakened by thymic atrophy. Secondly, its incidence is increased following the use of immunosuppressive drugs. Thirdly, the same effect is produced experimentally by thymectomy in mice. Fourthly, the rare diseases that involve a deficiency of cell-mediated immunity are characterized by a high incidence of tumours in those subjects who survive long enough to allow their development.
In the present paper we review only those parts of the evidence that have been obtained from observations on man.
Immunological Disorders
Consider first the frequency with The Chediak-Higashi syndrome is an autosomal recessive trait, characterized by distinctive granule-containing leucocytes, a pigment defect in the skin, hair, and eyes, and again a pronounced susceptibility to infection. In at least 11 out of the 50 reported cases a terminal illness has developed in which the appearance of the lymphoid tissue suggested a lymphoma. The nature of the immunological deficiency has not yet been discovered.'
